Tel Aviv, Israel, and Oslo, Norway, October 8, 2026
BioLineRx Ltd. and Hemispherian AS have announced that two abstracts featuring GLIX1, an investigational oral small-molecule therapy being developed for glioblastoma and other solid tumors, have been selected for poster presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting and Education Day. The meeting will take place from November 12 to 15, 2026, in Philadelphia, Pennsylvania, bringing together researchers and clinicians to discuss advances in brain tumor research and treatment. The presentations will cover preclinical findings evaluating GLIX1 across multiple glioblastoma models and the design of an ongoing Phase 1/2a clinical trial in patients with recurrent or progressive high-grade glioma and other solid tumors. GLIX1 is being developed through a collaboration between BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, and Hemispherian, a clinical-stage oncology company developing small-molecule therapeutics. The program focuses on TET2 activation and DNA damage response, an approach intended to investigate new treatment strategies for aggressive cancers. The presentations will provide an opportunity to share preclinical research and clinical development information with the neuro-oncology community as the companies continue evaluating GLIX1’s potential.
GLIX1 Preclinical Research Targets Glioblastoma
The first poster, abstract code EXTH-31, is titled “GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model.” It will be presented by Dr. Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian, on Friday, November 13, 2026, from 7:30 p.m. to 9:30 p.m. Eastern Standard Time at the Pennsylvania Convention Center, Exhibit Halls D and E. The presentation will describe preclinical research examining GLIX1 across different glioblastoma models, including orthotopic cell-line-derived xenograft (CDX) models and a subcutaneous patient-derived xenograft (PDX) model resistant to temozolomide (TMZ), a chemotherapy used in the treatment of certain brain tumors. These experimental models are used to investigate how potential therapies perform under different biological conditions. The study’s focus on treatment-resistant disease is particularly relevant to glioblastoma research, where therapeutic resistance and recurrence remain major challenges. The findings are preclinical and do not establish clinical benefit in patients. Further clinical evaluation will be needed to determine whether the observed laboratory activity translates into meaningful outcomes for people with glioblastoma.
Phase 1/2a Trial Evaluates GLIX1 in High-Grade Glioma
The second poster, abstract code CTNI-25, is titled “Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma.” The presentation will be delivered by Ditte Primdahl, MD, of Northwestern University Feinberg School of Medicine, on November 13, 2026, from 7:30 p.m. to 9:30 p.m. Eastern Standard Time at the same venue. It will describe the design of the ongoing early-stage clinical study investigating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors. BioLineRx initiated the Phase 1/2a trial in the first quarter of 2026, according to the company’s announcement. The clinical program is intended to evaluate the investigational candidate in people with advanced disease, with the early-stage study supporting further characterization of its clinical potential. GLIX1 remains an investigational therapy, and the announcement does not provide clinical efficacy results from the trial. Its safety, tolerability and potential therapeutic activity will need to be established through clinical evaluation and subsequent studies. The presentation is expected to help communicate the trial’s rationale and design to specialists working in neuro-oncology and cancer drug development.
Advertisement
BioLineRx and Hemispherian Advance Oncology Collaboration
BioLineRx and Hemispherian are collaborating to develop GLIX1 as part of their efforts to investigate innovative approaches for treating aggressive cancers. The candidate is described as an oral small molecule designed to target DNA damage response through TET2 activation. The companies are exploring its potential in glioblastoma, other high-grade gliomas and additional solid tumors. BioLineRx also has APHEXDA® (motixafortide), approved in the United States for stem cell mobilization for autologous transplantation in multiple myeloma, while retaining development rights for motixafortide in solid tumors, including metastatic pancreatic cancer. Hemispherian focuses on developing small-molecule cancer therapies and collaborates with academic and clinical institutions. The two GLIX1 presentations highlight both laboratory research and ongoing clinical development, providing updates on different stages of the candidate’s evaluation. Nevertheless, the selection of abstracts for presentation does not indicate regulatory approval or establish that GLIX1 is effective in treating brain cancer. Additional clinical data will be necessary to assess its potential role in future oncology treatment strategies.
Source: BioLineRx, Hemispherian press release
